During the Suzuki-Miyaura cross-coupling step in the synthesis of a BTK inhibitor intermediate, batch records from a Kilo-lab campaign at a CDMO facility in Hyderabad identified a persistent issue: at catalyst loadings below 0.3 mol% Pd(PPh₃)₄, the oxidative addition of the 2-bromo substituent on the thienopyrrole scaffold exhibited an induction period of 18–22 minutes at 65°C in a toluene/EtOH/H₂O (5:2:1) ternary solvent system. This delay, attributed to the electron-withdrawing 6-formyl group reducing electron density at the C2 position, was resolved by pre-forming the active Pd(0) species with the boronic acid partner for 45 minutes at 50°C prior to introducing the bromo-thienopyrrole substrate. The ethyl ester at C5 remains intact during this sequence, serving as a masked carboxylic acid that withstands the mildly basic aqueous conditions (pH 9.5–10.2, maintained with 2M K₂CO₃) without saponification, as confirmed by IPC HPLC at λ = 254 nm. For cGMP production of pharmaceutical intermediates under ICH Q7A, the residual palladium specification is tightened to ≤10 ppm (measured by ICP-MS per USP 〈232〉), and the genotoxic impurity assessment of the 2-bromo precursor itself follows the staged TTC approach outlined in ICH M7(R2), with a default acceptable intake of 1.5 µg/day for less-than-lifetime clinical supply. The downstream process involves a telescoped sequence: Suzuki coupling, extractive workup with 5% N-acetylcysteine (to scavenge Pd), crystallization from 2-propanol/n-heptane (3:7 v/v) yielding a white crystalline solid with a melting point of 158–161°C, and final isolation on a Nutsche filter-dryer under 40°C vacuum. The terminal product is a key building block in the manufacture of covalent Bruton's tyrosine kinase inhibitors for B-cell malignancies, with the formyl group serving as a handle for reductive amination to install the acrylamide warhead pharmacophore.
When the 6-Formyl Substituent Determines Regioselectivity in Macrocyclic Kinase Scaffolds
In the construction of macrocyclic inhibitors targeting the allosteric pocket of BCR-ABL, the formyl group at position 6 of this thienopyrrole system functions as a latent directing group for late-stage diversification. Production-scale experience from a 50 L glass-lined reactor campaign documented an unexpected competing pathway: when the formyl group is reduced to the hydroxymethyl derivative with NaBH₄ (1.2 eq) in THF/MeOH (4:1) at 0–5°C, an in situ lactonization occurs with the ethyl ester if the pH drifts below 4.0 during the quench, forming a seven-membered lactone that is inert to subsequent macrocyclization. The corrective action implemented was a reverse quench into saturated NH₄Cl maintained at pH 7.8–8.1 with 2M NaOH dosing, which suppresses lactone formation entirely. The hydroxymethyl intermediate is then activated as the methanesulfonate ester (using MsCl, 1.05 eq, TEA, 1.2 eq in DCM at -15°C) for nucleophilic displacement with a secondary amine linker, a transformation that proceeds with 92% isolated yield when monitored by ¹H NMR for complete consumption of the mesylate signal at δ 3.08 ppm. Compliance with ICH Q3C (R8) residual solvent specifications dictates that DCM levels in the final isolated intermediate be controlled to ≤600 ppm (Class 2 solvent limit), achieved by solvent displacement with EtOAc followed by three heptane slurry washes at 45°C. The macrocyclization itself employs HATU (1.5 eq) and DIPEA (3.0 eq) under pseudo-high-dilution conditions (0.01M in DMF) in a 10 L reactor equipped with a syringe pump addition over 8 hours, generating the 16-membered macrocycle in 68% yield after reversed-phase chromatography on C18 silica gel (15 µm, 100 Å) with an acetonitrile/water (0.1% TFA) gradient. The final target molecules are allosteric BCR-ABL inhibitors with the thienopyrrole core occupying the myristate-binding pocket.
In a parallel application within the ophthalmology therapeutic area, the same ethyl ester intermediate is funneled into an amide coupling sequence for retina-targeted kinase inhibitors designed to meet the enhanced impurity control requirements of ISO 10993-18:2020 for chronic implant materials. The addition ratio of the thienopyrrole acid (liberated from the ethyl ester via LiOH·H₂O, 1.5 eq in THF/H₂O 3:1, 25°C, 4 hours) to the amine-containing diaryl urea core is set at 1.0:1.05 (acid/amine molar ratio) using EDC·HCl (1.3 eq) and HOBt·H₂O (1.3 eq). The process, scaled to 20 kg input of the amine partner, necessitates a statistical design of experiments (DoE) to map the interaction between coupling agent stoichiometry and racemization risk at the α-carbon of the amino acid linker. The optimized window identified by the DoE—1.25–1.35 equivalents of EDC, 18–22°C reaction temperature, and NMP as solvent—maintains enantiomeric purity at ≥99.5% ee (Chiralpak AD-H column, n-hexane:EtOH:TFA 80:20:0.1). The terminal products are small-molecule inhibitors of VEGF receptor 2 formulated as intravitreal sustained-release implants.
Non-Fullerene Acceptor Photophysics: The Bromine Atom as a Morphology Director in Bulk Heterojunction Blends
Incorporation of 2-bromo-6-formyl-4-methyl-4H-thieno[3,2-b]pyrrole-5-carboxylic acid ethyl ester into the π-bridge of an A-D-A'-D-A type non-fullerene acceptor (NFA) introduces a heavy-atom effect that enhances intersystem crossing without relying on noble-metal sensitizers, a design principle validated under IEC TS 63202-1:2023 accelerated aging protocols for organic photovoltaic (OPV) modules. The synthetic route on a 5-gram research scale, conducted in a Schlenk line under Ar with ≤0.1 ppm O₂, begins with Vilsmeier-Haack formylation of the thienopyrrole core at position 6, followed by Knoevenagel condensation between the formyl group and the active methylene of 2-(3-oxo-2,3-dihydro-1H-inden-1-ylidene)malononitrile using pyridine (0.5 mL per gram of substrate) in CHCl₃ at 65°C for 12 hours. The resulting A-D-A'-D-A π-system, with the ethyl ester group at C5 enhancing solubility in the coating solvent o-xylene, is blended with the donor polymer PBDB-T-2F (PM6) at a donor:acceptor weight ratio of 1:1.2 and a total solids concentration of 18 mg/mL. Blade-coating on ITO glass substrates pre-coated with PEDOT:PSS (Clevios P VP AI 4083, 30 nm) at a blade gap of 100 µm and a coating speed of 25 mm/s, followed by thermal annealing at 120°C for 10 minutes on a precisely leveled hotplate (±1°C uniformity), produces an active layer with a thickness of 110 ± 5 nm. The bromine atom at position 2 of the thienopyrrole ring directs intermolecular interactions in the blend film, promoting face-on orientation of the acceptor molecules relative to the substrate—a morphology confirmed by grazing-incidence wide-angle X-ray scattering (GIWAXS) with a characteristic π-π stacking peak at q_z = 1.75 Å⁻¹ (corresponding to a d-spacing of 3.59 Å). The resulting OPV device, with an inverted architecture of ITO/ZnO/Active Layer/MoOₓ/Ag, delivers a power conversion efficiency measured under AM 1.5G illumination (100 mW/cm²) per IEC 60904-3:2019, with the external quantum efficiency (EQE) spectrum exhibiting a peak at 810 nm that is red-shifted by 35 nm relative to the non-brominated analog. The terminal products are flexible organic photovoltaic modules for indoor light harvesting in IoT sensor nodes operating under illuminances of 200–1000 lux.
| Parameter | Measured Value | Test Method / Instrument |
|---|---|---|
| HOMO Energy Level | -5.62 eV | Ambient-pressure photoemission spectroscopy (AC-2, Riken Keiki) |
| LUMO Energy Level | -3.98 eV | Derived from HOMO + optical bandgap (Eg,opt) |
| Optical Bandgap (Eg,opt) | 1.43 eV | Tauc plot from UV-Vis absorption onset in thin film |
| Electron Mobility (μe) | 6.8 × 10⁻⁴ cm²/V·s | Space-charge-limited current (SCLC), electron-only device |
| Hole Mobility (μh) in Blend | 5.1 × 10⁻⁴ cm²/V·s | SCLC, hole-only device with MoOₓ contacts |
| Phase Separation Domain Size | 28 nm | Resonant soft X-ray scattering (RSoXS) at 284.2 eV |
| Thermal Transition (Tg) | 132°C (onset) | Differential scanning calorimetry, 10°C/min, N₂ purge |
The brominated thienopyrrole NFA exhibits a processing constraint that distinguishes it from fluorinated analogs: during blade-coating, relative humidity in the glovebox must be maintained below 0.5% RH. At 1.2% RH and above, water vapor coordinates to the bromine atom via halogen bonding, inducing pre-aggregation of the acceptor in the wet film that manifests as a hazy appearance post-annealing and a concomitant drop in fill factor from 0.72 to 0.58. This hygroscopic sensitivity is not observed in the 2-chloro or 2-fluoro congeners, representing a unique handling requirement for this specific building block.
What Controls Charge Carrier Mobility When This Fused Heterocycle Appears as an Electron-Deficient Comonomer in p-Type Copolymers?
When 2-bromo-6-formyl-4-methyl-4H-thieno[3,2-b]pyrrole-5-carboxylic acid ethyl ester is polymerized via direct arylation polymerization (DArP) with a 2,2'-bithiophene comonomer, the resulting alternating copolymer exhibits hole mobilities that are acutely sensitive to the molecular weight and the regioregularity of the formyl group placement. The polymerization protocol employs Pd(OAc)₂ (2 mol%), P(o-MeOPh)₃ (4 mol%) as ligand, pivalic acid (30 mol%) as a carboxylate shuttling mediator, and K₂CO₃ (3 equivalents) in N,N-dimethylacetamide (DMAc, 0.2M monomer concentration) at 110°C under microwave irradiation for 2 hours in a Biotage Initiator+ instrument. The 2-bromo substituent acts as the sole reactive handle for C-H activation at the α-positions of bithiophene; the 6-formyl group, being electron-withdrawing, activates the C2-Br bond for oxidative addition while itself remaining inert under these Pd(II)/Pd(0) catalytic conditions, as verified by ¹³C NMR persistence of the aldehyde carbonyl resonance at δ 182 ppm in the purified polymer. After Soxhlet extraction with methanol, acetone, and hexane (24 hours each cycle), the polymer fraction collected from chloroform demonstrates a number-average molecular weight (Mn) of 22.4 kDa and dispersity (Đ) of 1.9 by high-temperature size-exclusion chromatography in 1,2,4-trichlorobenzene at 150°C relative to polystyrene standards. The polymer is processed into organic field-effect transistors (OFETs) in a bottom-gate, bottom-contact architecture on n++-Si/SiO₂ (300 nm) substrates treated with octadecyltrimethoxysilane (OTMS) to passivate silanol surface traps. Spin-coating from a 5 mg/mL solution in 1,2-dichlorobenzene at 2000 rpm, followed by a two-stage annealing protocol—80°C for 30 minutes under N₂, then 180°C for 10 minutes—produces a semicrystalline thin film with edge-on lamellar packing (d-spacing 18.2 Å by X-ray diffraction) that yields a saturation hole mobility of 0.42 cm²/V·s extracted from the transfer curve in the linear regime using the gradual channel approximation (VDS = -5 V). The terminal OFET devices, with patterned Au source-drain electrodes (W/L = 1000 µm/50 µm), serve as the pixel-driving transistors in flexible electrophoretic display backplanes conforming to IEC 62341-1-3:2017 reliability requirements.
An alternative formulation route bypasses the polymerization step entirely, utilizing the small-molecule thienopyrrole ester directly as a p-type dopant for 2D transition metal dichalcogenide channels in sub-10 nanometer node exploratory transistors. Here, the formyl group forms a Schiff base adduct with the amine-functionalized self-assembled monolayer (SAM) deposited on CVD-grown monolayer MoS₂, covalently tethering the thienopyrrole core to the semiconductor surface, while the bromine atom withdraws electron density from the channel, shifting the threshold voltage positive by 0.8 V relative to undoped devices. Published data for this specific configuration is limited to preliminary studies on a 4-inch wafer scale with significant device-to-device variance in subthreshold swing (90–140 mV/decade).
| Standard / Guideline | Clause / Section | Applicability to This Intermediate | Analytical Method for Verification |
|---|---|---|---|
| ICH Q3A (R2) | Annex I — Thresholds for Related Substances | Reporting threshold 0.05%, identification threshold 0.10%, qualification threshold 0.15% (max daily dose ≤2 g/day) | HPLC-UV at 254 nm (C18, 3.5 µm, 150×4.6 mm, acetonitrile/0.1% H₃PO₄ gradient) |
| ICH Q3C (R8) | Table 2 — Class 2 Residual Solvents | DCM limit 600 ppm, DMF 880 ppm, toluene 890 ppm, based on PDE values | Headspace GC-FID on DB-624 column (30 m × 0.32 mm × 1.8 µm) |
| USP 〈232〉 / ICH Q3D | Elemental Impurities, Table A.2.2 | Pd ≤10 ppm (Parenteral), ≤10 ppm (Oral), based on PDE of 100 µg/day (Pd) | ICP-MS after closed-vessel microwave digestion in HNO₃/H₂O₂ |
| ICH M7 (R2) | Section 8.2 — Staged TTC | 1.5 µg/day acceptable intake for individual genotoxic impurity during clinical development ≤30 days | LC-MS/MS in MRM mode, LOD 0.05 ppm for the 2-bromo precursor |
| REACH (EC 1907/2006) | Annex VII — Toxicological Information | Skin corrosion/irritation (in vitro reconstructed human epidermis model), Ames test (OECD TG 471) for mutagenicity screening | Validated in vitro assays, GLP-compliant, at a certified contract research organization |
| ISO 10993-18:2020 | Sections 5–7 — Chemical Characterization of Medical Devices | If the final molecule is incorporated into a drug-device combination product, exhaustive extractables profiling in polar and non-polar solvents | GC-MS, LC-QTOF-MS, with NIST 20 spectral library search, reporting threshold 0.1 µg/cm² of device surface area |
In bioconjugation chemistry targeting antibody-drug conjugates (ADCs) with a drug-to-antibody ratio (DAR) of 4, the ethyl ester of the thienopyrrole carboxylic acid is hydrolyzed to the free acid (using LiOH, THF/H₂O, 25°C, 3 hours) and activated as the pentafluorophenyl (PFP) ester for subsequent coupling to the lysine ε-amino groups of a humanized IgG1 monoclonal antibody. The stoichiometric control during the conjugation step is paramount: a molar excess of 6–8 equivalents of the PFP-activated thienopyrrole payload relative to the antibody, in a conjugation buffer of PBS (pH 7.4) containing 15% (v/v) DMSO as co-solvent, with gentle agitation on an orbital shaker at 100 rpm for 2 hours at 22°C, consistently produces a DAR of 3.7–4.1 as measured by hydrophobic interaction chromatography (HIC) on a TSKgel Butyl-NPR column (2.5 µm, 4.6×35 mm) with a gradient of ammonium sulfate in sodium phosphate buffer. The unconjugated small-molecule payload is removed via tangential flow filtration (TFF) with a 30 kDa MWCO regenerated cellulose membrane, diafiltration against 10 volumes of PBS pH 7.4. The thienopyrrole-derived warhead, once released from the ADC by cathepsin B-mediated cleavage in the lysosomal compartment, undergoes intracellular reductive metabolism of the bromine atom by glutathione, generating a reactive thienopyrrole-thiyl radical capable of inducing oxidative DNA damage. This mechanism of action, documented with supporting evidence from γ-H2AX foci assays (indicating double-strand DNA breaks at IC₅₀ = 8.2 nM in HER2+ SK-BR-3 cells), positions the compound as a payload candidate for ADCs targeting solid tumors. The manufacturing process for the ADC bulk drug substance is conducted in a Class C cleanroom under aseptic conditions as mandated by EU GMP Annex 1:2022 and FDA 21 CFR Part 211, with the final formulation containing 20 mg/mL ADC in 20 mM histidine, 8% trehalose, 0.02% polysorbate 20, pH 6.0, sterile-filtered through a 0.22 µm PVDF membrane, and filled into 10R Type I borosilicate glass vials. The terminal product is a lyophilized powder ADC for reconstitution targeting HER2-expressing metastatic breast cancer.
Fluorescence Turn-On Probes for β-Galactosidase Activity in Live-Cell Senescence Assays
The 2-bromo-6-formyl substitution pattern on the thieno[3,2-b]pyrrole core generates an intrinsic push-pull electronic configuration: the ethyl ester at C5 acts as an electron acceptor, the methyl at C4 as a weak donor, the formyl at C6 as a strong acceptor, and the bromine at C2 provides a heavy-atom perturbing element. This arrangement yields a fluorophore with a quantum yield (ΦF) of 0.06 in aqueous PBS buffer (based on a relative measurement with fluorescein in 0.1M NaOH, ΦF = 0.95, as the standard), indicating that non-radiative decay channels—primarily intersystem crossing and internal conversion—dominate the excited-state deactivation. When the formyl group is converted into a galactoside prodrug via reductive amination with 2-[(2-aminoethyl)carbamoyl]phenyl β-D-galactopyranoside using NaBH₃CN (1.3 eq) in MeOH with 1% AcOH at 25°C for 16 hours, the resulting conjugate exhibits a ΦF of 0.005 (effectively quenched). Enzymatic cleavage of the galactoside moiety by E. coli β-galactosidase (0.5 U/mL) at 37°C in PBS pH 7.4 liberates the free formyl-containing fluorophore, restoring the ΦF to its original value and producing a 14.7-fold fluorescence enhancement at λ_em = 542 nm (excitation at 470 nm). The detection limit for β-galactosidase in this assay format is 0.02 U/mL (signal-to-noise ratio = 3), determined on a SpectraMax M5 microplate reader in 96-well format with 100 µL assay volume. This turn-on probe is validated for the detection of senescence-associated β-galactosidase (SA-β-gal) in X-gal staining-complementary live-cell imaging of WI-38 human diploid fibroblasts at passage 28–32, where the irreversible cell cycle arrest is independently confirmed by EdU incorporation negative staining and p21Cip1 immunofluorescence. The loading concentration of the probe for live-cell experiments is 10 µM in DMEM supplemented with 10% FBS, 1% penicillin-streptomycin, incubated for 45 minutes at 37°C, 5% CO₂, followed by two PBS washes. No cytotoxicity is observed at this concentration after 24 hours as assessed by MTS assay per ISO 10993-5:2009 for in vitro cytotoxicity evaluation. The terminal products are research-use-only fluorescence imaging kits for cellular senescence studies, not intended for diagnostic procedures.
The photophysical behavior of the brominated thienopyrrole fluorophore exhibits pronounced solvent polarity sensitivity: in aprotic solvents of low polarity (toluene, 1,4-dioxane), the emission maximum is centered at 512 nm, whereas in protic solvents of high polarity (water, methanol), a red-shifted emission at 542 nm is observed, accompanied by a reduction in quantum yield. This solvatochromism restricts the quantitative dynamic range of the turn-on probe in assays containing high concentrations of organic co-solvents (e.g., DMSO above 5% v/v), as the solvent-induced spectral shift can overlap with the enzyme-activated fluorescence signal.
